Adial Pharmaceuticals ADIL shares are trading higher on Tuesday after the company announced the FDA has issued an emergency use authorization for the company's Assure/FaStep COVID-19 IgG/IgM rapid test device.
Adial Pharmaceuticals is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is an approved drug for treating nausea and emesis.
Adial Pharmaceuticals shares traded up 36.17% to $1.92 on Tuesday during the time of publication. The stock has a 52-week high of $3.17 and a 52-week low of $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
